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Abstract
Background: Several mechanisms are involved in the pathophysiology of the Acute Coronary Syndrome (ACS). We
have addressed whether B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP) in admission
samples may improve risk stratification in chest pain patients with suspected ACS.
Methods: We included 982 patients consecutively admitted with chest pain and suspected ACS at nine hospitals
in Salta, Northern Argentina. Total and cardiac mortality were recorded during a 2-year follow up period. Patients
were divided into quartiles according to BNP and hsCRP levels, respectively, and inter quartile differences in
mortality were statistically evaluated applying univariate and multivariate analyses.
Results: 119 patients died, and the BNP and hsCRP levels were significantly higher among these patients than in
survivors. In a multivariable Cox regression model for total death and cardiac death in all patients, the hazard ratio
(HR) in the highest quartile (Q4) as compared to the lowest quartile (Q1) of BNP was 2.32 (95% confidence interval
(CI), 1.24-4.35), p = 0.009 and 3.34 (95% CI, 1.26-8.85), p = 0.015, respectively. In the TnT positive patients (TnT >
0.01 ng/mL), the HR for total death and cardiac death in Q4 as compared to Q1 was 2.12 (95% CI, 1.07-4.18), p =
0.031 and 3.42 (95% CI, 1.13-10.32), p = 0.029, respectively.
The HR for total death for hsCRP in Q4 as compared to Q1 was 1.97 (95% CI, 1.17-3.32), p = 0.011, but this
biomarker did not predict cardiac death (p = 0.21). No prognostic impact of these two biomarkers was found in
the TnT negative patients.
Conclusion: BNP and hsCRP may act as clinically useful biomarkers when obtained at admission in a population
with suspected ACS.
Trial Registration: ClinicalTrials.gov Identifier: NCT01377402.
Background
M y o c a r d i a li n j u r yi nt h eA C Sm a yb ed e t e c t e db ya n
increase in the troponins, and among these TnT is con-
sidered to be a sensitive diagnostic marker in this condi-
tion. As the troponins are released as a result of
myocardial necrosis secondary to thrombus formation in
a coronary artery, they are not actively involved in the
pathophysiology of ACS. Therefore, several patients with
chest pain and ACS may exhibit normal levels of TnT in
the subacute period preceding a myocardial infarction
(MI).
The lack of diagnostic support during the early phases
before the thrombus formation has stimulated the search
for serum biomarkers, able to identify disease activity in
patients with a negative TnT. Such markers may alert the
clinician of an impending ACS in patients with chest
pain without troponin release. Strategies to combine
multiple biomarkers that may reflect diverse pathobiolo-
gical contributors to the occurrence and complications of
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assessment, targeting therapy more effectively. Proof-of-
principle has been established with evidence for
improved risk stratification using the combination of
BNP, hsCRP and cardiac troponin [1-4].
BNP is a counter-regulatory peptide hormone predo-
minantly synthesized in the ventricular myocardium, and
is released into the circulation in response to ventricular
dilatation and pressure overload [5,6]. It is a well known
marker of left ventricular dysfunction and heart failure
(HF) and it provides prognostic information beyond and
above left ventricular ejection fraction (LVEF) as well as
troponins in patients with ACS [7-10].
C-reactive protein (CRP) is an acute-phase reactant and
a marker for underlying systemic inflammation, including
atherosclerosis and plaque rupture with ensuing throm-
bus formation [11-13]. Through the use of appropriate
high-sensitive assays, it has been possible to investigate
the prognostic utility in cardiovascular disease (CVD) of
plasma CRP levels previously considered to be within the
normal range [14]. Burke and colleagues have suggested
that hsCRP in serum reflects the numbers of vulnerable
coronary atherosclerotic plaques in sudden cardiac death
(SCD) [15]. Nevertheless, the prognostic value of this
marker in CVD is still controversial [16,17] and its use in
this setting should be restricted to subjects at high risk of
CVD [1].
However, there are limited data available that prospec-
tively compare these two biomarkers in admission samples
from an unselected patient population presenting to the
emergency department (ED) with chest pain. Furthermore,
few trials have been conducted prospectively with this aim
in an Argentinean population. In addition, their role in
risk stratification of patients with ACS is still under eva-
luation, and therefore additional investigations are
necessary.
The aims of this study were to explore the ability of
BNP and hsCRP to predict risk of total and cardiac mor-
tality within 24 months in a consecutively hospitalized
patient population with chest pain and suspected ACS.
Methods
Study Design and Patient Population
T h i ss t u d yw a sar e g i o n a lm u l t i c e n t e rp r o g n o s t i cs t u d y
(ARRA-RACS: ARgentinean Risk Assessment Registry in
the Acute Coronary Syndrome) designed to evaluate pro-
spectively the prognostic impact of BNP and hsCRP in a
population consisting of 982 patients with chest-pain and
a suspected ACS, consecutively admitted to nine different
hospitals in Salta, Argentina from December 2005 to Jan-
uary 2009. Eight centers were private and one was public.
The latter included sixty-two patients (6.5%).
Patients entered into the registry were admitted for
ACS as a presumptive diagnosis and had to be alive at
the time of hospitalization. We used troponin-T levels
at baseline and at six hours after admission for disease
classification. Furthermore, BNP and hsCRP were deter-
mined in all patients as quality indicators in our registry.
Clinical data were collected at each site by a trained
coordinator using a standardized nine-page case report
form. Demographic characteristics, medical history, pre-
senting symptoms, biochemical and electrocardiographic
findings, treatment practices, and a variety of hospital
outcome data were collected. Recorded information also
included patient management data and outcome during
hospitalization as well as after discharge. The patients
received standard medical treatment at all centers. How-
ever, some patients needed to be referred to other more
specialized hospitals with cardiac catheterization labora-
tory facilities when intervention was required.
Main exclusion criteria were age < 18 years, unwilling-
ness or incapacity to provide informed consent and prior
inclusion in the present study. Four patients with missing
data for hsCRP were excluded from the present analysis.
The primary outcome measure of the present study was
all-cause mortality from the time of inclusion until two
year follow-up. The secondary outcome was cardiac death.
The term ACS in the present study encompasses
unstable angina pectoris (UAP), Non ST-segment Eleva-
tion Myocardial Infarction (NSTEMI) and ST-segment
Elevation Myocardial Infarction (STEMI). The following
classification for the index diagnosis was used: STEMI;
ST-segment elevation combined with TnT values > 0.03
ng/mL. NSTEMI; Transient ST-segment elevation, ST-
segment depression, or T-wave inversion in at least 2
contiguous leads combined with TnT values > 0.03 ng/
mL. UAP; Transient ST-segment depression or T-wave
inversion and TnT values ≤ 0.03 ng/mL, or borderline
TnT values above 0.01 ng/mL up to 0.03 ng/mL without
ECG changes. No-ACS: All other conditions (i.e. unspeci-
fic chest pain, arrhythmias, atrial fibrillation etc.) without
ECG changes and with negative troponins. The definition
of cardiac death included death, preceded by a definitive
myocardial infarction or by chest pain > 20 minutes with-
out a given TnT, or a history of ischemic heart disease
and no other obvious cause of death [18].
Survival status, date and cause of death were obtained
by an office visit at 12 months and telephone interview at
30 days, 6, and 24 months during the 2-year follow-up
period. The family, neighbours and the national registry
department were contacted to obtain relevant informa-
tion regarding relocations. Information related to cause
of death was obtained through official records and addi-
tional information was supplied by close family members.
Laboratory parameters and clinical parameters, includ-
ing age, gender, assessment of previous MI, angina pec-
toris, previous revascularizations [percutaneous coronary
intervention (PCI) or coronary artery bypass graft
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Killip-Kimball class [19], diabetes mellitus (DM), smok-
ing status (categorized as current smokers, previous
smokers or never-smokers), hypercholesterolemia
(defined as total cholesterol concentrations above
250 mg/dl or statin treated hypercholesterolemia), beta-
blockers and arterial hypertension (defined as repeated
blood pressure measurements above 140/90 mmHg or
treated hypertension) were based on hospital records
and personal interviews. Electrocardiographic (ECG)
findings at admission were classified according to the
presence of ST-segment changes (i.e. ST-segment
depression or elevation, T-wave inversion or left bundle-
branch block).
Written informed consent was obtained from all
patients. The study was approved by the Ethics Committee
at the Board of Medical School of Salta and conducted in
accordance with the Helsinki declaration of 1971, as
revised in 1983. At two hospitals the study also needed to
be approved by a local hospital ethics committee or insti-
tutional review board. The Norwegian biobank containing
Argentinean blood samples was approved by the Regional
Board of Research Ethics and the Norwegian health
authorities.
Blood Sampling Procedures and Laboratory
Measurements
Peripheral blood samples for determination of TnT, crea-
tinine, glucose, lipids and hsCRP in serum and BNP in
EDTA (ethylene diamine tetraacetic) acid plasma, were
drawn immediately following admission by direct veni-
puncture of an antecubital vein, applying a minimum of
stasis. A repeated blood sample for the determination of
TnT was drawn six hours following the primary blood
sample. Clotted whole blood and EDTA blood samples
were centrifuged for 15 min with 2000 x g at 20°C with-
out delay. Serum and EDTA plasma were immediately
frozen in three aliquots, stored locally at -70°C and trans-
ferred in frozen condition (dry ice) to Stavanger, Norway
in three different shipments after collection of the first
100 samples, the next 400 samples and finally the
remaining samples, respectively. These samples remained
stored in a Norwegian biobank at -70°C until measure-
ments were performed.
TnT was quantified by a cardiac-specific second-genera-
tion troponin T ELISA assay from Roche diagnostics,
using a high-affinity cardiac-specific TnT isoform antibody
[20]. The lower detection limit of the assay used is
0.01 ng/mL. In this study a cut off level of 0.01 ng/mL was
used with a coefficient of variation (CV) of 10%.
BNP was analysed in EDTA plasma using the Micro-
particle Enzyme Immunoassay (MEIA) Abbott AxSYM
®
(Abbott Laboratories, Abbott Park, Illinois, USA). The
dynamic range was 0-4000 pg/mL and the within-run
coefficient of variation (CV) was 6.3% at 95 pg/mL and
4.7% at 1587 pg/mL, respectively.
HsCRP was measured with the use of an immunoturbi-
dimetric assay (Tina-quant
® C-reactive protein (latex)
high sensitive assay, Roche Diagnostics, Germany) per-
formed on a Roche automated clinical chemistry analyzer
(MODULAR P). The detection limit was 0.03 mg/L and
the measuring range 0.1-20.0 mg/L with an extended mea-
suring range with automatic re-run 0.1-300 mg/L. The
between-assay CV was 3.45% at 1.19 mg/L and 2.70% at
0.43 mg/L, respectively.
Statistical analysis
The patients were divided into quartiles according to
their BNP and hsCRP levels. Approximately normally
distributed variables were given as mean and standard
deviation (SD), whereas variables with skewed distribu-
tions were given as median and quartiles. The Chi-square
test for association was applied between both the BNP
and hsCRP quartiles and categorical variables at baseline.
The one-way ANOVA test was used to test for equality
of means of scale variables (e.g. age) amongst quartiles,
and the two-sample t test and Mann Whitney test were
used for comparing the means and medians of two sam-
ples, respectively. The hazard ratios (HR) are presented
with 95% confidence interval (CI). Stepwise Cox multi-
variable proportional hazards regression models with
total death and cardiac death as the dependent variables
and BNP, hsCRP quartiles and other variables as poten-
tial independent predictors (listed below) were fitted. To
examine the differences in prognosis between subjects in
the upper versus the lower quartile of BNP and hsCRP,
w ea d j u s t e df o ra g e ,s e x ,s m o k i n g ,h y p e r t e n s i o n ,i n d e x
diagnosis, creatinine, diabetes mellitus, CHF (defined by
Killip-Kimball class at admission, those patients in class 2
to 4 were classified as CHF patients and non CHF for
c l a s s1 ) ,h i s t o r yo fp r e v i o u sC H D( i . e .h i s t o r yo fe i t h e r
angina pectoris, MI, CABG or PCI), hypercholesterole-
mia/use of statins, TnT > 0.01 ng/mL and beta-blockers
prior to enrolment. The Kaplan-Meier product limits
were used for plotting the times to event. In the discrimi-
nate analyses BNP, CRP, loge (BNP) and loge (CRP) were
used as individual variables. The statistical analyses were
performed using the statistical package SPSS version
19.0. All tests were two-sided with a significance level of
5%.
Results
A total of 982 patients were enrolled in the ARRA-
RACS study. No hsCRP samples were available for four
patients.
No patient was lost to follow-up at two years. At index
hospitalization, 388 patients (39.5%) had a peak TnT con-
centration exceeding 0.01 ng/mL. 16.8% of the patients
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class 3 and 4.
The baseline characteristics of the patients, stratified
according to BNP and hsCRP quartiles at admission are
listed in Tables 1 and 2, respectively. The median BNP
and hsCRP concentrations in plasma were 78.1 (35.8-
179.7) pg/mL [25 and 75% percentiles] and 3.1 (1.3-8.4)
mg/L [25 and 75% percentiles], respectively. Patients
with BNP in the higher quartiles were significantly older
and had a higher proportion of patients with a TnT
exceeding 0.01 ng/ml. Furthermore, there were more
past smokers and patients with established coronary
heart disease and heart failure in the higher quartiles,
and creatinine also increased significantly.
The differences between the upper and lower quartiles
of hsCRP were not quite as pronounced as for BNP.
However, as for BNP, patients were older and a higher
proportion of patients had TnT exceeding 0.01 ng/ml.
BNP, CRP, loge (BNP) and loge (CRP) were used as
individual variables in a discriminate analysis with the pur-
pose to identify patients with true ACS versus non-cardiac
chest pain at index admission and to predict fatal outcome
in the total population and in the TnT negative (TnT ≤
0.01 ng/mL) and TnT positive (TnT > 0.01 ng/mL) subpo-
pulations. In the univariate discriminate analyses, a TnT
positive event at admission was correctly classified by BNP
in 66.7% and by hsCRP in 64.2% of cases in their non-
logarithmic form and slightly less in their logarithmic
form. The specificity of non-logarithmic BNP and hsCRP
for predicting all-cause mortality in the total population
was 89.6% and 90.3%, respectively, with a sensitivity of
44.5% and 31.9%, respectively (Table 3).
Combining the two predictors in our quartile compar-
isons did not increase the prognostic impact as com-
pared to the separate analysis of BNP and hsCRP.
All-Cause Mortality
Total Patient Population
A f t e raf o l l o w - u pp e r i o do f2 4m o n t h s ,1 1 9p a t i e n t s
(12.2%) had died. Kaplan-Meier survival curves for the
primary endpoint according to BNP and hsCRP quartiles
at baseline are presented in Figures 1 and 2, respectively,
(the log rank test for each was 0.000). The BNP and
hsCRP levels were significantly higher among patients
dying than in 2-year survivors; 228 (66-603) versus 72
(34-148) pq/mL [median, 25 and 75% percentiles], p =
0.000 and 7.8 (2.3-35.6) versus 2.9 (1.3-7.5) mg/L [med-
ian, 25 and 75% percentiles], p = 0.000, respectively.
Receiver operated characteristics (ROC) curves for
B N P ,h s C R Pa n dT n Ta r es h o w ni nF i g u r e3 .T h ea r e a
under the ROC for BNP, hsCRP and TNT was 0.711 (p =
0.000), 0.666 (p = 0.000) and 0.666 (p = 0.000),
respectively.
In a stepwise multivariate Cox regression model, BNP
was found to be a prognostic indicator of 2 year total
mortality in the total patient population. The HR for
BNP in Q4 was 2.32 (95% CI, 1.24-4.35) as compared to
Q1, which was statistically highly significant, p = 0.009.
Table 1 Baseline characteristics for patient strata according to quartiles of BNP
Quartiles of BNP pg/mL
Characteristics < 36 36-78 79-180 181-4000 p value
Age; years ± SD 57.9 ± 12.4 60.7 ± 11.5 62.7 ± 13.9 67.4 ± 13.8 0.000
Female n (%) 95(38.8) 96(39.0) 94(38.2) 109(44.5) 0.453
Hypertension n (%) 142(58.0) 157(63.8) 173(70.3) 162(66.1) 0.036
DM n (%) 46 (19.1) 45 (18.4) 43 (17.6) 68(28.3) 0.012
Current Smoker n (%) 90(37.5) 57(23.5) 51(20.9) 41(17.1) 0.000
Past Smoker n (%) 113(47.3) 130(53.9) 140(57.6) 154(64.4) 0.000
Angina Pectoris n (%) 45(18.4) 47(19.1) 68(27.6) 63(25.7) 0.028
CHF n (%)
Killip-Kimball Class 2-4
33(13.5) 44(17.9) 33(13.4) 55(22.4) 0.021
MI n (%) 6(2.4) 21(8.5) 32(13) 35(14.3) 0.000
CABG n (%) 3(1.2) 10(4.1) 14(5.7) 20(8.3) 0.003
PCI n (%) 17(6.9) 23(9.3) 30(12.2) 28(11.4) 0.208
STEMI n (%) 36(14.9) 23(9.5) 40(16.5) 45(18.8) 0.030
TnT Positive n (%) 67(27.5) 65(26.4) 100(40.7) 156(63.7) 0.000
Creatinine n (%)
(above median)
113(46.3) 111(45.1) 118(48.4) 143(58.6) 0.011
Cholesterol/Statin n (%) 31(12.7) 40(16.3) 49(19.9) 40(16.3) 0.191
Beta-blocker n (%) 53(21.9) 50(20.5) 76(31.1) 74(31.1) 0.006
CHD n (%) 56(23.0) 71(29.1) 98(40.0) 99(40.9) 0.000
BNP, brain natriuretic peptide; DM, diabetes mellitus; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI,
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TnT, troponin-T; cholesterol = conc. > 250 mg/dl; CHD, coronary heart disease
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also showed a significant relation to prognosis, with a
HR of 1.97 (95% CI, 1.17-3.32), p = 0.011.
Troponin-T Positive Patients
In the 388 patients admitted with TnT release we found
that 82 patients (21.1%) had died during the 2-year fol-
low-up. The BNP levels were significantly higher among
patients dying than in the 2-year survivors. In the uni-
variate analysis for BNP the HR was 3.83 (95% CI, 2.05-
7.15), p = 0.000, and in a stepwise multivariable Cox
regression model, the HR was 2.12 (95% CI, 1.07-4.18),
p = 0.031, remaining significant when age, CHF and
CHD were added.
The hsCRP levels were also significantly higher among
TnT positive patients with fatal events than in survivors.
In the univariate analysis the HR was 3.10 (95% CI, 1.67-
5.75, p = 0.012, and in the multivariable model the HR for
hsCRP was 3.27 (95% CI, 1.71-6.24), p = 0.000, remaining
significant when age, sex and CHF were added.
Kaplan-Meier plots for the cumulative risk of total
mortality in the TnT positive patients for BNP and
hsCRP quartiles are presented in Figure 4.
Troponin-T Negative Patients
A f t e raf o l l o w - u pp e r i o do f2 4m o n t h s ,3 7p a t i e n t s
(6.3%) of 590 with negative TnT results had died. In
this group, neither BNP nor hsCRP added any prognos-
tic information. Kaplan-Meier plots for the cumulative
risk of total mortality in the TnT negative patients for
BNP and hsCRP quartiles are presented in Figure 5.
Cardiac Death
Total Patient Population
A f t e raf o l l o w - u pp e r i o do f2 4m o n t h s ,6 6p a t i e n t s
(6.9%) had experienced cardiac death.
In the univariate analysis for the total population, the
HRs for BNP and hsCRP were 6.97 (95% CI, 2.94-16.54),
Table 2 Baseline characteristics for patient strata according to quartiles of hsCRP
Quartiles of hsCRP mg/L
Characteristics < 1.3 1.4-3.1 3.2-8.4 8.5-350.8 p value
Age; years ± SD 60.2 ± 13.7 60.9 ± 13.6 63.9 ± 12.2 63.7 ± 13.6 0.002
Female n (%) 85(34.7) 100(40.5) 113(46.3) 94(38.8) 0.070
Hypertension n (%) 160(65.3) 157(63.6) 162(66.4) 153(63.2) 0.870
DM n (%) 39(16) 45(18.6) 53(22.1) 64(26.7) 0.026
Current Smoker n (%) 58(24.2) 57(23.6) 67(27.9) 55(22.8) 0.572
Past Smoker n (%) 140(58.1) 139(58.2) 126(52.7) 130(54.4) 0.582
Angina Pectoris n (%) 48(19.6) 59(23.9) 60(24.6) 55(22.7) 0.563
CHF n (%)
Killip-Kimball Class 2-4
29(11.8) 34(13.8) 51(20.9) 50(20.7) 0.009
MI n (%) 19(7.8) 22(8.9) 21(8.6) 31(12.8) 0.233
CABG n (%) 11(4.5) 12(5.0) 12(5.0) 11(4.6) 0.991
PCI n (%) 25(10.2) 29(11.7) 27(11.1) 16(6.6) 0.235
STEMI n (%) 24(10.0) 32(13.3) 45(18.9) 41(17.0) 0.029
TnT Positive n (%) 62(25.3) 82(33.3) 111(45.5) 130(53.7) 0.000
Creatinine n (%)
(above median)
117(47.8) 115(46.6) 117(48.0) 136(56.2) 0.126
Cholesterol/Statin n (%) 43(17.6) 42(17.0) 42(17.2) 33(13.6) 0.621
Beta-blocker n (%) 78(32.1) 64(26.6) 57(23.8) 53(22.1) 0.064
CHD n (%) 71(29.1) 84(34.4) 86(35.70) 82(33.9) 0.435
hsCRP, high sensitive C-reactive protein; DM, diabetes mellitus; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI,
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TnT, troponin-T; cholesterol = conc. > 250 mg/dl; CHD, coronary heart disease
Table 3 Discriminate analysis of all cause mortality using
BNP, hsCRP and their natural logarithm, for total
population, TnT positive patients, and TnT negative
patients, respectively
Population BNP CRP Log(BNP) Log(CRP)
All Specificity 89.6 90.3 71.2 69.6
Sensitivity 44.5 31.9 65.5 61.0
Overall 84.2 83.2 70.5 68.6
p value 0.000 0.000 0.000 0.000
TnT positive Specificity 86.5 85.7 65.3 65.8
Sensitivity 41.5 32.9 67.1 56.8
Overall 76.9 74.4 65.7 69.3
p value 0.000 0.001 0.000 0.000
TnT negative Specificity 88.1 92.2 69.1 65.5
Sensitivity 40.5 24.3 61.8 51.4
Overall 85.1 88.0 68.7 64.6
p value 0.000 0.000 0.000 0.001
BNP, brain natriuretic peptide; hsCRP, high sensitive C-reactive protein; TnT,
troponin-T
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tively. In a stepwise multivariable Cox regression model,
the HR for BNP was 3.34 (95% CI 1.26-8.85), p = 0.015,
whereas the HR for hsCRP was not significant, p = 0.21.
Troponin-T Positive Patients
The BNP levels in the TnT positive patients were signif-
icantly higher among those with cardiac death than in
survivors (200.5 (79.5-612.4) versus 73.9 (35.0-159.3)
mg/dl [median, 25 and 75% percentiles], p = 0.000).
In this subgroup, the HRs for BNP were 7.07 (95% CI,
2.45-20.46), p = 0.000 and 3.42 (95% CI, 1.13-10.32), p =
0.029, in the univariate and multivariate analyses, respec-
tively. The impact of BNP in Q4 remained significant
when age was added to the multivariable model.
In the TnT positive patients the hsCRP levels were
also significantly higher among patients with cardiac
death than in those that did not have a cardiac death
(9.6 (3.0-44.9) versus 4.4 (1.9-12.6) mg/L [median, 25
and 75% percentiles], p = 0.012). Comparing Q4 to Q1
in the multivariate Cox regression model, the HR for
hsCRP for cardiac death in the TnT positive patients
was 3.05 (95% CI, 1.31-7.11) and reached statistical sig-
nificance, p = 0.010, but its significance was attenuated
(p = 0.33) when adjusted for BNP.
Troponin-T Negative Patients
Neither BNP nor hsCRP added any prognostic informa-
tion in this subpopulation.
Discussion
The present prospective observational study was care-
fully designed to meet the requirements for a prognostic
evaluation of biomarkers. Contrary to randomized stu-
dies, patients are unselected and included on a consecu-
tive basis which offers a great advantage for risk
identification.
In this study we have included admission samples of
the two biomarkers BNP and hsCRP, to investigate their
impact on prognosis in patients with chest pain and sus-
pected ACS, and we have discriminated between patients
with and without a release of TNT.
Figure 1 Kaplan-Meier plots for the cumulative risk of total mortality for the BNP quartiles.
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natriuretic peptides and CRP may yield incremental
prognostic information in the risk stratification of
patients with ACS [2,3], and their combined use has
been shown to improve long-term risk prediction of
mortality in patients with stable coronary heart disease
(CHD) [4].
In the stepwise multivariate model applied to the total
chest-pain patient material we included the presence
and absence of a TnT release and were able to demon-
strate a statistical significant prognostic impact of BNP
and hsCRP, respectively, on 2 year survival, both for
total and cardiac mortality.
In the TnT positive subgroup we found a statistically
significant prognostic impact of BNP in the stepwise
multivariate Cox regression model on all cause mortality
and cardiac mortality, whereas hsCRP was found to be
related only to total mortality.
In a univariate discriminant analysis we found that a
TnT positive event was correctly classified by BNP or
hsCRP in over 60% of cases. The specificity of BNP and
hsCRP for predicting all cause mortality of the total
population was around 90% for both biomarkers, asso-
ciated with a sensitivity of 44.5 and 31.9%, respectively.
In the present study, patients in the highest quartile of
both BNP and hsCRP were older and a higher proportion
had a TnT exceeding 0.01 ng/ml. In the highest quartile
of BNP there were also more past smokers and subjects
with established CHD and HF, and creatinine was also
increased. These differences reflect the increased burden
of risk in the upper quartiles of BNP and hsCRP, respec-
tively. Despite some similarities in underlying risk bur-
den, these two predictors are mechanistically different.
However, their combination did not strengthen the prog-
nostic utility.
Our results indicate that both BNP and hsCRP are
major predictors of outcome in a population in which
invasive coronary intervention is less available as com-
pared to wealthier communities, as only 29% of the total
population and 38% of the TnT positive population
underwent a revascularization procedure during the hos-
pitalization for the index event.
Figure 2 Kaplan-Meier plots for the cumulative risk of total mortality for the hsCRP quartiles.
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classified as STEMIs, and of these patients only 42%
were treated with primary PCI. Furthermore, the use of
thrombolytic therapy in this region of Argentina is
uncommon and was not applied in our patient cohort.
The less frequent use of reperfusion treatment in
STEMI patients makes this population unique in an
epidemiological setting, optimizing an evaluation of
Figure 3 Receiver operated characteristic curve for BNP, hsCRP and TnT for evaluation of all-cause mortality in total patient
population.
Figure 4 Kaplan-Meier plots for the cumulative risk of total mortality in the TnT positive patients.
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Page 8 of 11prognostic indicators in relation to the natural course of
disease.
The results of this observational study is in accordance
with previous studies investigating the prognostic impact
of BNP [21] and hsCRP [22], and also emphasize the
importance of several clinical background factors in this
respect [23-25]. After adjusting for clinical covariates, the
prognostic utility of BNP as well as hsCRP remained sta-
tistically significant with respect to total mortality in both
the total population and in the TnT positive patients.
It was shown in the mid 90-ies that elevated troponins
are associated with a worsened prognosis in ACS patients
[26]. Since then, a considerable number of publications
h a v ev e r i f i e dt h ep r o g n o s t i cs i g n i f i c a n c eo ft h i sb i o m a r -
ker in this patient setting [27]. Its prognostic utility
exceeds that of all other biomarkers, including BNP [8]
and hsCRP [14].
Based on previous studies [14,15,22,28] addressing the
prognostic utility of hsCRP, this biomarker has been con-
sidered for adoption into risk assessment algorithms
[1,29]. Recently conducted studies show that the predictiv-
ity of hsCRP is attenuated when tested in a multivariable
model in the general population [30] and together with
natriuretic peptides in patients with known CAD [31-34].
In our study hsCRP seems to be a potential predictor for
all cause mortality, also when adjusted for BNP, but does
not reflect cardiac mortality in the TnT positive popula-
tion when introducing BNP into the model.
In contrast to hsCRP, natriuretic peptides integrate spe-
cific pathophysiological signals, especially relating to ven-
tricular dysfunction [5,35] and ischemic burden [9]. The
main prognostic impact of BNP was found in the TnT
positive patients, suggesting a relation to ischemia.
The measurement of prognostic biomarkers has often
been performed in randomized interventional trials several
days following the onset of symptoms and hospitalization
[8,10,29]. In contrast to the majority of previous studies
investigating the prognostic impact of various biomarkers,
our study had a prospective and observational design, and
blood samples were collected directly on admission.
Few studies have examined the predictive value of
natriuretic peptides across the spectrum of chest-pain
patients with suspected ACS in blood samples obtained
directly on admission before introduction of therapy [22].
Therefore, in the present study which is similar to a pre-
vious study performed by our group [36], we do not have
to consider the potential confounding factors of late
inclusions and recently introduced medical treatment.
Similar considerations apply to the measurement of
hsCRP.
A major strength of this study is the absence of patients
lost to follow-up and there were only four patients with
no measurements available for hsCRP. Moreover, our
study was performed in an inhomogeneous and unse-
lected chest-pain population with suspected ACS which
is representative of the one commonly dealt with in the
ED.
Our study suggests that BNP and/or hsCRP in addition
to the troponins may be supplementary biomarkers in
risk stratification. However, their impact in the clinical
prognostic assessment of ACS patients depends on the
presence of troponin release. By including patients with
borderline troponin levels ≤ 0.05 ng/mL among the TnT
negative patients and without adjusting for a positive tro-
ponin value, the HR of BNP for cardiac death in Q4 as
compared to Q1 in the multivariate Cox regression
model was 3.58 (95% CI, 1.02-12.60), p = 0.047, in this
extended patient category. The same relation was
observed for hsCRP; HR of 2.69 (95% CI, 1.22-5.95), p =
0.015, suggesting that the use of BNP or hsCRP may
strengthen the clinical prognostic assessment in this
subgroup.
Figure 5 Kaplan-Meier plots for the cumulative risk of total mortality in the TnT negative patients.
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The potential limitations of these data merit considera-
tion. The circulating concentrations of BNP and hsCRP
prior to hospitalization remain unknown and our ana-
lyses are based on a single baseline determination.
Although we did not adjust for LVEF, we did adjust for
known CHF and CVD, including previous MI, and other
clinical risk factors.
Conclusion
BNP and hsCRP may act as clinically useful prognostic
biomarkers when obtained at hospital admission in an
unselected chest-pain population with potential ACS, and
may improve risk stratification in troponin positive
patients. However, these biomarkers failed to identify
patients at risk in the troponin negative population.
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